Journal of Clinical Oncology
Articles in this Issue
Immunohistochemical and gene expression profiles as predictors of survival in recurrent high-grade glioma treated with intracranial nivolumab, ipilimumab, and autologous CD1c(BDCA-1) <sup>+</sup> /CD141(BDCA-3) <sup>+</sup> myeloid dendritic cells (myDC).
2071 Background: Innovative treatments are needed for recurrent high-grade glioma (rHGG) patients (pts) as current salvage therapies fail to improve overa...
Single low-dose 5-mg versus 8-mg dexamethasone with NEPA for the 168-h prevention of highly or moderately emetogenic (high-risk patients) chemotherapy-induced nausea/vomiting: An open-label, randomised, controlled, phase 3 trial.
12072 Background: Tailoring Dexamethasone (DEX) dosing to reduce corticosteroid exposure is a challenging issue in the chemotherapy induced nausea /vomiti...
First in human PK analysis of antibody conjugated liposome encapsulating doxorubicin (HF-K1) in advanced cancer patients: Comparison with ADCs.
e15011 Background: Antibody drug conjugates (ADCs) have been shown to have a better therapeutic index however there have been reports of serious toxicity...
Dynamic longitudinal patient cohorts using hospital electronic medical record (EMR) data via secure data environment (SDE) technology to generate real-world evidence (RWE).
e23320 Background: Patient cohorts using clinically rich Real-World Data (RWD) extracted from medical records have been used to generate RWE. These patien...
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.
510 Background: Carboplatin-based regimen are effective in patients (pts) with eTNBC, and olaparib improves the outcome of pts with BRCA1/2...
Informing the gravid void: A population-based study of live birth rates after oncologic immunotherapy in reproductive age women.
e14654 Background: Immunotherapy is a new standard oncologic treatment modality in nearly every organ system, however fertility sequalae are yet to be def...
Impact of radiation dose in multi-isocentric volumetric arc-based total body irradiation on oncological outcomes in allogenic stem cell transplantation.
e18551 Background: Total body irradiation (TBI) remains a cornerstone in conditioning regimens for patients undergoing allogenic stem cell transplantation...
Development and validation of a multi-feature immune scoring prognostic model for stage II and III rectal cancer patients.
e15636 Background: Stage II and III rectal cancer patients undergoing direct surgery after clinical diagnosis remain at risk of postoperative recurrence,...
Analysis of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh).
4539 Background: We previously reported on treatment intensification with the combination of Cabo/Nivo/Ipi in 39 patients (pts) with metastatic RCCdh in a...
A phase I study of allogeneic anti-CD19 CAR-T therapy for patients with CD19+ relapsed/refractory acute B-lymphoblastic leukemia.
6525 Background: Acute B-lymphoblastic leukemia (B-ALL), characterized by CD19 expression, responds well to CD19-targeted CAR-T therapy. However, autologo...
Pregnancy during cancer treatment: A population-based analysis.
e12560 Background: We sought to assess maternal and neonatal outcomes of patients who became pregnant while undergoing treatment for cervical, ovarian, or...
Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.
4515 Background: VEGFR-targeted tyrosine kinase inhibitors (TKIs) in combination with immune checkpoint inhibitors (ICIs) are standard of care for previou...
DOACs vs warfarin: Rethinking anticoagulation strategies for portal vein thrombosis prophylaxis in patients with increased risk.
e23352 Background: Portal vein thrombosis (PVT)—the formation of a thrombus within the portal vein or its branches (superior mesenteric and splenic veins)...
An overview of survival and demographic disparities in primary peritoneal carcinoma: Insights from Surveillance, Epidemiology, and End-Results (SEER) database (2000 to 2021).
e23346 Background: Primary peritoneal carcinoma (PPC) is a rare and aggressive malignancy arising from the peritoneal lining with minimal or no ovarian in...
Age matters: Real-world evidence of increased immunotherapy toxicity in elderly patients from a Brazilian oncology hospital.
e23258 Background: Immunotherapy with immune checkpoint inhibitors (ICI) is widely used in cancer treatment. While effective, ICIs can cause immune-mediat...
Transcriptomic insights into the prognostic role of mean platelet volume and ferroptosis in immunotherapy-treated metastatic clear cell renal cell carcinoma.
e16506 Background: Immune checkpoint inhibitor (ICI)-based treatments have revolutionized the management of clear cell renal cell carcinoma (ccRCC), but m...
Microbiome-metabolomics analysis for biomarker identification in liver cancer among Rio Grande Valley Hispanics.
e16268 Background: Rio Grande Valley (RGV) Hispanic population is a major hotspot for hepatocellular carcinoma (HCC) and liver diseases. HCC often develop...
Real-world survival outcomes of patients with de novo stage IV melanoma: A 13-year single center experience.
e21526 Background: Survival outcomes of patients with unresectable melanoma improved with the advent of checkpoint inhibitors (ICI) and BRAF/MEK inhibitor...
Preventative intervention uptake among women with breast cancer and pathogenic germline variants.
10570 Background: Risk-reducing (RR) interventions in patients (pts) with pathogenic germline variants (PGV) in breast cancer (BC) risk genes include RR m...
Hot flashes and night sweats in women with breast cancer: Prevalence and severity of symptoms.
12053 Background: Hot flashes(HF) and night sweats(NS) are common endocrine-related symptoms experienced by breast cancer patients, which potentially aris...
Targeting the TGFβ signaling pathway to mitigate tumor metastasis in 9p21-loss urothelial bladder cancer.
4566 Background: We previously identified that 9p21-loss (containing MTAP and CDK2NA genes) occurs in 25% of metastatic urothelial cancer (mUC) and is ass...
The significance of relative dose intensity of CAPOX therapy in epidemiological evaluation of gastric cancer outcomes.
e16081 Background: Epidemiological studies on drug therapy outcomes in specific populations are crucial for post-marketing surveillance (PMS), especially...
Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT.
6554 Background: SER-155 is an investigational, oral, live biotherapeutic product (LBP) comprised of 16 bacterial strains designed to decolonize gastroint...
Efficacy of systemic therapy in breast cancer with CNS metastases: “Real-world” experience.
2025 Background: The incidence of CNS metastases in breast cancer is rising. While local therapies such as surgery and radiation remain standard, data on...
Postoperative adjuvant therapy with donafenib in hepatocellular carcinoma with high-risk recurrence factors: A real-world, prospective, observational study.
e16316 Background: The five-year recurrence rate of hepatocellular carcinoma (HCC) after hepatic resection is as high as 70% and remains a major clinical...